- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
Novo Nordisk submitted a new dose for its obesity drug, driven by intensifying competition in the weight loss market.
1 report, 0 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk submitted a new dose for its obesity drug, driven by intensifying competition in the weight loss market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.Also in this story
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Mounjaro's approval caused a decline in Trulicity sales, marking a specific development in the weight loss drug market.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.
Coverage
Newest first; wire copies grouped- Unknown outlet